PubMed · 13302584
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
A H WHITTAKER. 1956. Disability evaluation.. https://doi.org/10.1016/0002-9610(56)90308-7
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
OBJECTIVE: The purpose of this study was to estimate the correlation between the voice handicap index (VHI) and the voice related quality of life (VRQOL) questionnaire with respect to gender and diagnosis (functional vs organic dysphonia). MATERIALS AND METHODS: A total of 52 German speaking patients aged 48.8+/-22.0 years suffering from dysphonia of different benign etiologies (functional dysphonia: 18 women, 9 men; organic dysphonia: 13 women, 12 men) completed German versions of both the VHI and the VRQOL questionnaire without prior information on their individual diagnosis. Another 52 individuals without voice complaints served as age and sex matched controls. Complete data sets of all participants were analyzed using the Microsoft Excel and MATLAB software packages. RESULTS: The results of both questionnaires correlate at a significant level, both for total score (r=-0.9) and the subscores (r=-0.74-r=-0.84) with only slight differences when comparing women and men and patients with functional and organic voice disorders. CONCLUSIONS: Both questionnaires provide very similar results. Thus, for clinical purposes, it seems justified to restrict oneself to using only one of the questionnaires. Whenever basic information on the patients' self perception of a voice disorder is required, the VRQOL questionnaire with only ten items may be easier to handle than the VHI questionnaire with 30 items.
OBJECTIVE: To assess the long-term effectiveness of continuous glatiramer acetate (GA) therapy in relapsing-remitting multiple sclerosis (RRMS). METHODS: This open-label extension followed a randomized, placebo-controlled, double-blind study of GA of approximately 30 months duration. Patients originally randomized to GA continued on it (group A) and those randomized to placebo switched to GA (group B). RESULTS: Of 251 original patients, 142 (56.6%) remained in the study after 8 years. Annual relapse rate for both groups declined to approximately 0.2 (approximately one relapse every 5 years). However, a significantly larger proportion of patients in group A had stable or improved Expanded Disability Status Scale scores compared with group B (65.3% vs 50.4%, respectively; P = 0.0263), possibly attributable to the delay of GA treatment for approximately 30 months in group B. GA was well tolerated and no drug-related laboratory changes were observed. CONCLUSIONS: These data support early initiation of GA therapy as an efficacious and well-tolerated long-term treatment for RRMS patients.
Explore the source record for details and available documents.